Evaluation of powder mixtures and hydrophilic gastroretentive drug delivery systems containing zinc acetate and sodium bicarbonate

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 4, 2011, Pages 711-716

  Baki, Gabriella ^a   Bajdik, János ^a   Pintye Hódi, Klára ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Disintegration; Dissolution; Floating; Sodium bicarbonate; Water uptake; Zinc acetate dihydrate

Indexed keywords

BICARBONATE; HYDROXYPROPYLMETHYLCELLULOSE; ZINC ACETATE;

ARTICLE; DEGRADATION; DISSOLUTION; DRUG DELIVERY SYSTEM; EFFERVESCENT TABLET; HYDROPHILICITY; POWDER; PRIORITY JOURNAL; TABLET FORMULATION; WATER TRANSPORT;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; GASTRIC JUICE; GASTROINTESTINAL TRANSIT; HEPATOLENTICULAR DEGENERATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; METHYLCELLULOSE; MODELS, CHEMICAL; PHYSICOCHEMICAL PHENOMENA; POWDERS; SODIUM BICARBONATE; SOLUBILITY; TABLETS; VISCOSITY; WATER; ZINC ACETATE;

EID: 78650250587     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.10.026     Document Type: Article

References (35)

1. Hefti A.F., Huber B. The effect on early plaque formation, gingivitis and salivary bacterial counts of mouthwashes containing hexetidine/zinc, aminefluoride/tin or chlorhexidine. J. Clin. Periodontol. 2005, 14:515-518.
2. Little P. Zinc acetate lozenges reduced the duration and severity of symptoms of the common cold. Evid. Based Med. 2001, 6:46.
3. Frydman M. Genetic aspects of Wilson's disease. J. Gastroenterol. Hepatol. 1990, 5:483-490.
4. Bull P.C., Thomas G.R., Rommens J.M., Forbes J.R., Cox D.W. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat. Genet. 1993, 5:327-337.
5. Tanzi R.E., Petrukhin K., Chernov I., Pellequer J.L., Wasco W., Ross B., et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet. 1993, 5:344-350.
6. Nagy J., Vincze Z., Folhoffer A., Horváth A., Csák T., Zelkó R. The pathomechanism and treatment of Wilson disease. Acta Pharm. Hung. 2004, 73:237-241.
7. Hoogenraad T.U., Van Hattum J., Van den Hamer C.J. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J. Neurol. Sci. 1987, 77:137-146.
8. Hoogenraad T.U., Koevoet R., de Ruyter Korver E.G. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur. Neurol. 1979, 18:205-211.
9. Brewer G.J., Dick R.D., Johnson V.D., Brunberg J.A., Kluin K.J., Fink J.K. Treatment of Wilson's disease with zinc. XV. Long-term follow-up studies. J. Lab. Clin. Med. 1999, 132:264-278.
10. Schilsky M., Blank R.R., Czaja M.J., Scheinberg I.H., Stockert R.J., Sternlieb I. Hepatocellular copper toxicity and its attenuation by zinc. J. Clin. Invest. 1989, 84:1562-1568.
11. Hill G.M., Brewer G.J., Prasad A.S., Hydrick C.R., Hartmann D.E. Treatment of Wilson's disease with zinc. I. Oral zinc therapy regimens. Hepatology 1987, 7:522-528.
12. Cousins R.J. Absorption, transport and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol. Rev. 1985, 65:238-309.
13. Brewer G.J., Hill G.M., Prasad A.S., Cossack Z.T., Rabbani P. Oral zinc therapy for Wilson's disease. Ann. Intern. Med. 1983, 99:314-319.
14. Roberts E.A., Schilsky M.L. A practice guideline on Wilson disease. Hepatology 2003, 37:1475-1492.
15. Krebs N.F., Westcott J.E., Huffer J.W., Miller L.V. Absorption of exogenous zinc and secretion if endogenous zinc in the human small intestine. FASEB J. 1998, 12:A345. 345-348.
16. Lee H.H., Prasad A.S., Brewer G.J., Owyang C. Zinc absorption in human small intestine. Am. J. Physiol. 1989, 256:G87-G91.
17. Bernkop-Schnürch A. Mucoadhesive systems in oral drug delivery. Drug. Discov. Today 2005, 2:83-87.
18. Wang J., Tabata Y., Bi D., Morimoto K. Evaluation of gastric mucoadhesive properties of aminated gelatin microspheres. J. Control Release 2001, 73:223-231.
19. Fix J.A., Cargill R., Engle K. Controlled gastric emptying. Part 3. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm. Res. 1993, 10:1087-1089.
20. Atyabi F., Sharma H.L., Mohammad H.A.H., Fell J.T. In vivo evaluation of a novel gastric retentive formulation based on ion exchange resins. J. Control Release 1996, 42:105-113.
21. Iannuccelli V., Coppi G., Sansone R., Ferolla G. Air compartment multiple-unit system for prolonged gastric residence. Part II. In vivo evaluation. Int. J. Pharm. 1998, 174:55-62.
22. Sungthongjeen S., Paeratakul O., Limmatvapirat S., Puttipipatkhachorn S. Preparation and in vitro evaluation of a multiple-unit floating drug delivery system based on gas formation technique. Int. J. Pharm. 2006, 324:136-143.
23. 2 gas-forming agents. Int. J. Pharm. 2002, 239:81-91.
24. Jiménez-Martínez I., Quirino-Barreda L., Villafuerte-Robles Sustained delivery of captopril from floating matrix tablets. Int. J. Pharm. 2008, 362:37-43.
25. Rouge N., Buri P., Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int. J. Pharm. 1996, 136:117-139.
26. Dave B.S., Amin A.F., Patel M.M. Gastroretentive drug delivery system of ranitidine hydrochloride: formulation and in vitro evaluation. AAPS Pharm. Sci. Technol. 2004, 5:A34. 1-6.
27. Sriamornsak P., Thirawong N., Korkerd K. Swelling, erosion and release behaviour of alginate-based matrix tablets. Eur. J. Pharm. Biopharm. 2007, 66:435-450.
28. Kudela V. Hydrogels. Encyclopedia of Polymer Science and Engineering 1987, vol. 7:703-807. Wiley, New York.
29. Cedillo-Ramírez E., Hernández-León A., Villafuerte-Robles L. Effect of added pharmatose DCL11 on the sustained-release of metronidazole from Methocel K4M and Carbopol 971P NF floating matrices. Drug Dev. Ind. Pharm. 2006, 32:955-965.
30. 2 impurities. Appl. Phys. Lett. 2005, 86:073111. 1-3.
31. Xiaoqiang X., Minjie S., Feng Z., Yiqiao H. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers. Int. J. Pharm. 2006, 310:139-145.
32. Hagers Handbuch der Pharmazeutischen Praxis 1991, 60. Springer Verlag, Berlin. 5th ed., Bd. 2 Methoden. E. Nürnberg, P. Surmann (Eds.).
33. Kelly K.A. Motility of the stomach and gastroduodenal junction. Physiology of the Gastrointestinal Tract 1981, vol. 1:393-410. Raven Press, New York. 1st ed.
34. Klausner E.A., Lavy E., Friedman M., Hoffman A. Expandable gastroretentive dosage forms. J. Control Release 2003, 90:143-162.
35. Rowe C.R., Sheskey P.J., Weller P.J. Handbook of Pharmaceutical Excipients 2003, Pharmaceutical Press, London, 263-265. 4th ed.